// App-Quantinova.ai

: Blinatumumab Induces Responses in Extramedulary B-Cell Acute Lymphoid Leukemia (B-ALL) and Lymphoid Blast Crisis Chronic Myelogenous Leukemia (CML), and Rarely Results in CD19 Negative Relapse

Researchers

Presenter

  • Jamie Koprivnikar

Principal Investigators

  • Danielle Marcotulli

  • Elizabeth Jones

  • Grace Perry

  • Yen-Hong Kuo

  • Joelle Gagnon

  • Maritess Aviador

  • Genique Stanislaus

  • James McCloskey

Medical Centers

  • John Thuerer Cancer Center, Hackensack Medical Center, NJ

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Office of Research Administration, Hackensack Meridian Health, Hackensack Medical Center, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Chronic Myelogenous Leukemia

  • Cytokine release syndrome

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • Ponatinib

  • dasatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved